(Q47332473)

14 January 2018

title

Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer (English)

1 reference

14 January 2018

1 reference

11

Roy S Herbst

1 reference

14 January 2018

Kurt A Schalper

12

object named as

Kurt A Schalper

1 reference

14 January 2018

author name string

Franz Villarroel-Espindola

1

1 reference

14 January 2018

Xiaoqing Yu

2

1 reference

14 January 2018

Ila Datar

3

1 reference

14 January 2018

Nikita Mani

4

1 reference

14 January 2018

Miguel F Sanmamed

5

1 reference

14 January 2018

Vamsidhar Velcheti

6

1 reference

14 January 2018

Konstantinos N Syrigos

7

1 reference

14 January 2018

Maria I Toki

8

1 reference

14 January 2018

Hongyu Zhao

9

1 reference

14 January 2018

Lieping Chen

10

1 reference

14 January 2018

language of work or name

English

0 references

publication date

4 December 2017

1 reference

14 January 2018

published in

Clinical Cancer Research

1 reference

14 January 2018

New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses.

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Pembrolizumab for the treatment of non-small-cell lung cancer

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Objective measurement and clinical significance of TILs in non-small cell lung cancer

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

PD-1 blockade induces responses by inhibiting adaptive immune resistance

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Characterization of programmed death-1 homologue-1 (PD-1H) expression and function in normal and HIV infected individuals

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Coinhibitory receptor PD-1H preferentially suppresses CD4⁺ T cell-mediated immunity

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

VISTA Regulates the Development of Protective Antitumor Immunity

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

VISTA is an immune checkpoint molecule for human T cells

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Programmed death ligand-1 expression in non-small cell lung cancer

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Inhibitory B7-family molecules in the tumour microenvironment

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

29 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5884702

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response

29 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29203588

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-17-2542

1 reference

14 January 2018

release_ibd5t4chnvgkndm6rtbpbgnjxq

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ibd5t4chnvgkndm6rtbpbgnjxq

mapped directly with Wikidata item

24 November 2022

based on heuristic

0 references

1 reference

14 January 2018